Dominic Piscitelli - 01 Feb 2023 Form 4 Insider Report for Oric Pharmaceuticals, Inc. (ORIC)

Role
Chief Financial Officer
Signature
/s/ Christian Kuhlen, attorney-in-fact
Issuer symbol
ORIC
Transactions as of
01 Feb 2023
Net transactions value
$0
Form type
4
Filing time
02 Feb 2023, 15:11:20 UTC
Previous filing
17 Feb 2023
Next filing
19 Dec 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORIC Stock Option (right to buy) Award $0 +145,000 $0.000000 145,000 01 Feb 2023 Common Stock 145,000 $6.00 Direct F1
transaction ORIC Restricted Stock Unit Award $0 +24,000 $0.000000 24,000 01 Feb 2023 Common Stock 24,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option shall vest on February 1, 2024, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock.
F3 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.